CHO-H01 + lenalidomide

CHO-H01 + lenalidomide is an investigational combination therapy for hematological malignancies, specifically non-Hodgkin's lymphoma. **CHO-H01** is a glycoengineered monoclonal antibody targeting CD20, designed to enhance effector functions like antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), as well as inducing apoptosis in target B cells. Compared to its non-glycoengineered parental antibody, CHO-H01 has increased binding affinity to FcγRIIIa and superior activity against B-cell lymphoma, including types resistant to rituximab. **Lenalidomide** is a small molecule, immunomodulatory agent and thalidomide analogue that acts via degradation of specific transcription factors (Ikaros IKZF1, Aiolos IKZF3), anti-angiogenic, anti-neoplastic, and immunomodulatory mechanisms, including enhanced NK cell activity and cytokine modulation. The combination is being evaluated for synergistic antitumor efficacy in low-grade, relapsed or refractory CD20+ non-Hodgkin's lymphoma in ongoing clinical trials[1][2][3][5][7].

Brand names

Revlimid (for lenalidomide)

Other names

glycoengineered anti-CD20 antibody + lenalidomide